Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis
To the Editor: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute and lifethreatening drug reactions characterized by extensive mucocutaneous exfoliation. SJS and TEN occur rarely, with an annual incidence of 1.2 to 9.2 and 0.4 to 1.9 per million, respectively. 1, 2 Wound care for SJS and/or TEN mirrors local trends in burn management, as current guidelines lack strong evidence for these pathologic processes. [3] [4] [5] The aim of this review is to assess the effects of dressings used in the wound care in patients with SJS and/or TEN and present evidence rated according to the Strength of Recommendation Taxonomy criteria that will aid clinicians in determining the best approach to wound care for their patients with SJS and/or TEN.
A review of the literature describing wound management in patients with SJS and TEN was conducted as outlined in Supplemental Fig 1 (available at http://www.jaad.org). The search terms used were (((''toxic epidermal necrolysis'' [Supplementary Concept]) OR ''toxic epidermal necrosis'' OR ''Stevens Johnson syndrome'') AND (biosynthetic OR collagen OR debridement OR dressing OR silver OR topical OR wound )). All retrospective studies, case reports, and case series describing wound management in patients with SJS and/or TEN were included. A total of 22 articles that included the primary outcome of time to reepithelialization (average time, 14.16 6 9.42 days) were selected. Table I 6-27 summarizes the results. Simple dressings (topical creams or ointments covered with bandages) and modern dressings ( fiber, biologic, and synthetic) were studied. The most commonly used dressings in the wound care of patients with SJS and/or TEN were biosynthetic dressings, followed by silver-impregnated fiber dressings. Table II A total of 13 studies used a concomitant systemic medication. Systemic steroids and intravenous immunoglobulin were the most frequently used. Whether any of these systemic medications affected time to re-epithelialization remains to be determined. No randomized clinical trials or studies with large power were found in our search. No studies met grade A or B Strength of Recommendation Taxonomy criteria (Table I ). The limitations of the studies selected include small sample sizes, use of systemic medication, and variation of time to diagnosis and time to placement of dressings. There was a lack of studies comparing 2 or more wound care interventions.
In conclusion, the use of modern dressings should be considered as part of standard therapy because of less frequent dressing changes and improved reported patient comfort. Further clinical studies are warranted, as their influence on healing time is yet to be determined. Ex vivo evaluation of cytotoxicity and melanocyte viability after A-101 hydrogen peroxide topical solution 40% or cryosurgery treatment in seborrheic keratosis lesions
To the Editor: Seborrheic keratosis (SK) is one of the most common types of dermatologic lesions and is, therefore, the most common skin tumor seen by dermatologists in everyday practice. 1 Currently, cryosurgery is one of the most commonly employed and successful techniques to physically resolve an SK. 2 However, all patients are susceptible to some degree of blistering, infection, scarring, recurrence, and pigmentary changes after treatment, but darkerskinned individuals are particularly vulnerable to the last 3 adverse events. 3 To help predict the potential toxicologic impact of A-101, a recently Food and Drug Administrationeapproved topical 40% hydrogen peroxide solution for the treatment of SK, 4 compared with the gold standard cryosurgery, we evaluated skin architecture, metabolic activity, and cytotoxicity with a particular emphasis on melanocytes, using a validated ex vivo human reconstituted full thickness model derived from Fitzpatrick V skin (MRHE). 5 MRHEs were treated with cryosurgery (5-second and 10-second freeze cycles) or A-101 (1 L and 2 L) and analyzed by MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] assay, Fontana-Masson, TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), and S100 immunohistochemical staining to determine skin architecture, metabolic activity, and cytotoxicity. Histologic evaluation of untreated and A-101 vehicleetreated tissues revealed a normal stratum corneum, with spinous and basal cell layers overlying a well-organized dermis with scattered fibroblasts. MRHEs treated with cryosurgery for 5 s or 10 s both demonstrated overall thinning of the epidermis, with more pyknotic cells noted in the deeper spinous layer of the 10-second specimens. In both groups, dermal-epidermal junction separation was noted, though more prominent in the 10-second group. In both A-101etreated groups, acanthosis of the epidermis and mild pallor was noted, though not to the extent of the cryosurgery-treated specimens, without epidermal clefting (data not shown).
To quantify the degree of epidermal damage incurred by treatment with cryosurgery or A-101, TUNEL staining was utilized to identify apoptotic (Fig 1, A) . Cellular metabolic activity was assessed using MTT assay, showing reduced metabolic activity indicative of reduced viability in cryosurgery-treated MRHE samples compared with A-101etreated groups (Fig 1, B) .
Within HPFs, untreated and vehicle-treated MRHEs were found to have 2.5 6 0.1987 melanocytes and 2.0 6 0.5000 melanocytes, respectively, based on S100 staining (Fig 1, C ) . After cryosurgery for 5 s and 10 s, the number of melanocytes were 0.45 6 0.1535 cells and 0.2 6 0.0918 cells, respectively, and after A-101 treatment for 1 L and 2 L, 1.95 6 0.1535 cells and 1.95 6 0.1535 cells, respectively.
Together, we show that cryosurgery is more cytotoxic than A-101, with special consideration of melanocyte survival. Our data suggests that A-101 might be a less caustic option for SK removal that reduces the risk of posttreatment pigmentary alterations. However, to best appreciate these findings, a clinical study that examines the risk for hypopigmentation or hyperpigmentation in darker skin types after A-101 treatment is warranted and is ongoing (ClinicalTrials.gov Identifier: NCT03224598). 
